Company intelligence / Profile preview

MBF Therapeutics

Ambler, Pennsylvania, United States

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

MBF Therapeutics has developed a proprietary T-Max™ DNA vaccine platform targeting infectious diseases and cancer in animals. Their lead program—a canine melanoma vaccine—has completed a Phase I study demonstrating safety and strong immune responses. The company also pursues gene-based checkpoint inhibitors for both oncology and infectious disease applications. They are advancing preclinical programs for major animal health threats such as PRRS and African swine fever.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA vaccinesGene-based checkpoint inhibitorsImmunotherapies (T cell vaccines)Adenoviral vectored products
Industry: Veterinary

Partnerships

Seeking partnerships with major animal/vaccine companies; specific partners not listed.

Beyond the preview

Go deeper on MBF Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBF Therapeutics.

Explore the full profile